CN Patent

CN110772521A — Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途

Assigned to Suzhou Yasheng Pharmaceutical Co ltd · Expires 2020-02-11 · 6y expired

What this patent protects

本发明涉及一种包含Bcl‑2抑制剂(或Bcl‑2/Bcl‑xL抑制剂)和BTK抑制剂的组合产品，所述组合产品提供了在预防和/或治疗疾病(例如，癌症、自身免疫性疾病和炎性疾病)的用途。

USPTO Abstract

本发明涉及一种包含Bcl‑2抑制剂(或Bcl‑2/Bcl‑xL抑制剂)和BTK抑制剂的组合产品，所述组合产品提供了在预防和/或治疗疾病(例如，癌症、自身免疫性疾病和炎性疾病)的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN110772521A
Jurisdiction
CN
Classification
—
Expires
2020-02-11
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Yasheng Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.